MENU
Home
Add Document
Sign In
Create An Account
PDF Reader
Full Text
© 1990 Nature Publishing Group
Suggest Documents
Bush veto fuels orphan drug act uncertainties.
Evolution and current status of the Orphan Drug Act.
Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase.
Drug development. Orphan drug windfalls?
Generic drug companies are the winners.
Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Glycoprotein pharmaceuticals: scientific and regulatory considerations, and the US Orphan Drug Act.
Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
Diazoxide--an orphan drug?
Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.
From promising molecules to orphan drugs: Early clinical drug development.
Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
Letter: "Orphan-drug" development - whose responsibility?
Rare lung disease and orphan drug development.
Judge upends 340B orphan drug exclusion.
Editorial: Orphan GPCRs As Emerging Drug Targets.
A new kind of orphan drug?
The evolving drug development landscape: from blockbusters to niche busters in the orphan drug space.
Challenges to replace ACT as first-line drug.
1978 Drug Regulation Reform Act.
The Massachusetts drug formulary act.
O'Grady pays tribute to our winners.
EU and in Latin America.
Congress Award Winners.
Orphan Drug Act. Winners to keep all.
© 1990 Nature Publishing Group...
144KB Sizes
0 Downloads
0 Views
Download PDF
Recommend Documents
Bush veto fuels orphan drug act uncertainties.
Evolution and current status of the Orphan Drug Act.
Creating the costliest orphan. The Orphan Drug Act in the development of Ceredase.
Drug development. Orphan drug windfalls?
Generic drug companies are the winners.
Novel Treatments for Rare Cancers: The U.S. Orphan Drug Act Is Delivering-A Cross-Sectional Analysis.
Glycoprotein pharmaceuticals: scientific and regulatory considerations, and the US Orphan Drug Act.
Pressure for drug development in lysosomal storage disorders - a quantitative analysis thirty years beyond the US orphan drug act.
Diazoxide--an orphan drug?
Some Numbers behind Canada's Decision to Adopt an Orphan Drug Policy: US Orphan Drug Approvals in Canada, 1997-2012.
×
Sign In
Login with Facebook
Don't have an account?
Forgot Password?
×
Sign Up
By clicking register, I agree to your terms